Plan sponsor implications Alberta Blue Cross frames the 2026 pipeline report as a tool to help plan sponsors anticipate new cost drivers and high-impact therapies, supporting what it calls informed decision making on proactive benefit management strategies to balance patient access with sustainable plan design [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
This FDA-approved medication works by regulating appetite, reducing cravings, and improving how your body manages energy, making it a powerful option for those looking to lose weight effectively
The article says timing is a useful clue
Buse, M.D., from the University of North Carolina School of Medicine in Chapel Hill, and colleagues randomly assigned 2,713 adults with inadequately controlled type 2 diabetes receiving metformin with or without SGLT2i with overweight or obesity to receive cagrilintide-semaglutide, semaglutide, cagrilintide, or placebo for 68 weeks
EMPA and LINA were dissolved with CMC and administrated by oral gavage
laws and regulations, including to the extent applicable Section 14(e) of the U.S
